the last trial they had they narrowly missed the os endpoint, this time i expect them to get it right this time, i mean come on really, they got two years and if they cant do it this time i dont really know what to say then
That is a totally FALSE and MISLEADING statement.
First, it is the SAME trial. What they did was take the data from the FAILED trail, and said- "if you consider only these people, it worked". Now think about that for a second. Couldn't you do that for just about any trial?
The FDA has a long record AGAINST data-mined information to try to support compounds that failed a trial's primary end-points, then are repackaged based on a data mined sub-set.
Second- Two years? Really? Most new drugs take 10 years to get from concept to approval. And the approval rate from concept to approval is less than 2%. Most drugs FAIL. A New Drug Application submission take 6-12 months to prepare, then the FDA can take up to a year to review the data and make a decision. Even if the OS data was VERY positive, my guess would be they could file in the fall and be waiting until the summer of next year to get approval.
They have enough money to last until MAYBE August or September. Plus they have so much debt that they will have to issue 5.5 BILLION more shares to just take care of the OLD finance people. They they will have to do it again. Yes, it will be easier if they have positive OS data, but for someone holding 100K shares today, worth about $4100, this will be a nightmare. Your shares are already scheduled to be diluted by 11 times the current worth, then they have to do another deal. So your 100,000 shares, if bought today and fully diluted, are worth $372, or 0.00372 per share. AND THAT IS BEFORE THEY DO ANOTHER DEAL.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.